Literature DB >> 17329499

Selective activation of liver X receptors by acanthoic acid-related diterpenes.

Paqui G Traves1, Sonsoles Hortelano, Miriam Zeini, Ta-Hsiang Chao, Thanh Lam, Saskia T Neuteboom, Emmanuel A Theodorakis, Michael A Palladino, Antonio Castrillo, Lisardo Bosca.   

Abstract

Terpenoids constitute a large family of natural steroids that are widely distributed in plants and insects. We investigated the effects of a series of diterpenes structurally related to acanthoic acid in macrophage functions. We found that diterpenes with different substitutions at the C4 position in ring A are potent activators of liver X receptors (LXRalpha and LXRbeta) in both macrophage cell lines from human and mouse origin and primary murine macrophages. Activation of LXR by these diterpenes was evaluated in transient transfection assays and gene expression analysis of known LXR-target genes, including the cholesterol transporters ABCA1 and ABCG1, the sterol regulatory element-binding protein 1c, and the apoptosis inhibitor of macrophages (Spalpha). Moreover, active diterpenes greatly stimulated cholesterol efflux from macrophages. It is interesting that these diterpenes antagonize inflammatory gene expression mainly through LXR-dependent mechanisms, indicating that these compounds can activate both LXR activation and repression functions. Stimulation of macrophages with acanthoic acid diterpenes induced LXR-target gene expression and cholesterol efflux to similar levels observed with synthetic agonists 3-[3-[N-(2-chloro-3-trifluoromethylbenzyl)-(2,2-diphenylethyl)-amino]propyloxy]phenylacetic acid hydrochloride (GW3965) and N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]phenyl]-benzenesulfonamide [T1317 (T0901317)]. These effects observed in gene expression were deficient in macrophages lacking both LXR isoforms (LXRalpha,beta(-/-)). These results show the ability of certain acanthoic acid diterpenes to activate efficiently both LXRs and suggest that these compounds can exert beneficial effects from a cardiovascular standpoint through LXR-dependent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329499     DOI: 10.1124/mol.106.031906

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Macrophage fatty-acid synthase deficiency decreases diet-induced atherosclerosis.

Authors:  Jochen G Schneider; Zhen Yang; Manu V Chakravarthy; Irfan J Lodhi; Xiaochao Wei; John Turk; Clay F Semenkovich
Journal:  J Biol Chem       Date:  2010-05-17       Impact factor: 5.157

2.  Activating PI3-kinase to dampen inflammation.

Authors:  Bernard P Kok; Enrique Saez
Journal:  Chem Biol       Date:  2014-08-14

Review 3.  Role of Liver X Receptor in Mastitis Therapy and Regulation of Milk Fat Synthesis.

Authors:  Xiaoyu Hu; Naisheng Zhang; Yunhe Fu
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-07-31       Impact factor: 2.673

4.  Cot/tpl2 (MAP3K8) mediates myeloperoxidase activity and hypernociception following peripheral inflammation.

Authors:  Irene Soria-Castro; Agnieszka Krzyzanowska; Marta López Pelaéz; Javier Regadera; Gema Ferrer; Lluis Montoliu; Rosario Rodríguez-Ramos; Margarita Fernández; Susana Alemany
Journal:  J Biol Chem       Date:  2010-08-24       Impact factor: 5.157

Review 5.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

Review 6.  Ligands of Therapeutic Utility for the Liver X Receptors.

Authors:  Rajesh Komati; Dominick Spadoni; Shilong Zheng; Jayalakshmi Sridhar; Kevin E Riley; Guangdi Wang
Journal:  Molecules       Date:  2017-01-05       Impact factor: 4.411

7.  Selective partial agonism of liver X receptor alpha is related to differential corepressor recruitment.

Authors:  Caroline A Phelan; Joseph M Weaver; David J Steger; Shree Joshi; Jeffrey T Maslany; Jon L Collins; William J Zuercher; Timothy M Willson; Max Walker; Michael Jaye; Mitchell A Lazar
Journal:  Mol Endocrinol       Date:  2008-07-31

Review 8.  Natural Products Targeting Liver X Receptors or Farnesoid X Receptor.

Authors:  Jianglian She; Tanwei Gu; Xiaoyan Pang; Yonghong Liu; Lan Tang; Xuefeng Zhou
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.